See the DrugPatentWatch profile for Reclast
What is Reclast and how does it treat osteoporosis?
Reclast, also known as zoledronic acid, is a bisphosphonate medication used to treat osteoporosis. It works by slowing down bone loss and increasing bone density, thereby reducing the risk of fractures [1]. The drug is administered intravenously once a year for postmenopausal osteoporosis and every two years for men with osteoporosis [2].
How long does Reclast treatment typically last?
The duration of Reclast treatment for osteoporosis can vary. For postmenopausal osteoporosis, it is typically administered once a year. For men with osteoporosis, it is given every two years [2]. However, the optimal duration of treatment and the need for treatment cessation or continuation is a subject of ongoing clinical evaluation and depends on individual patient factors and response to therapy.
What are the potential side effects of Reclast?
Common side effects associated with Reclast include flu-like symptoms, such as fever, headache, and muscle aches, which may occur shortly after infusion [3]. Less common but more serious side effects can include kidney problems, particularly with rapid infusion or in patients with pre-existing kidney issues [3]. There is also a risk of osteonecrosis of the jaw (ONJ) and atypical femur fractures, although these are rare [3].
How does Reclast compare to other osteoporosis treatments?
Reclast is an intravenous bisphosphonate, differing from oral bisphosphonates like alendronate (Fosamax) or risedronate (Actonel) in its route and frequency of administration. Oral bisphosphonates are taken daily, weekly, or monthly [4]. Other classes of osteoporosis medications include denosumab (Prolia), a RANKL inhibitor, and anabolic agents like teriparatide (Forteo) and abaloparatide (Tymlos), which stimulate bone formation [4].
When does Reclast's patent protection expire?
Information regarding the specific patent expiry for Reclast is proprietary and not publicly detailed in the provided context. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when generic versions may become available [5].
What are the risks of discontinuing Reclast?
Discontinuing Reclast treatment can lead to a loss of bone density and an increased risk of fractures, as the protective effects of the medication diminish over time [6]. For some individuals, rebound vertebral fractures have been reported after stopping zoledronic acid therapy [7].
Are there any specific patient groups for whom Reclast is not recommended?
Reclast is not recommended for individuals with severe kidney disease or hypocalcemia (low blood calcium levels) [3]. It is also generally not recommended for pregnant or breastfeeding women [3].
What clinical data supports the use of Reclast for osteoporosis?
Clinical trials have demonstrated that Reclast significantly reduces the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis [1]. Studies have also shown its efficacy in increasing bone mineral density and reducing fracture risk in men with osteoporosis [2].
Where can I find more information on Reclast and its patents?
For comprehensive information on Reclast, including its clinical use, side effects, and patent status, resources like DrugPatentWatch.com are valuable [5].
---
Sources:
[1] https://www.rxlist.com/script/main/mobilearticleread.asp?articlekey=228523&ref=1
[2] https://www.reclast.com/how-to-take-reclast/
[3] https://www.webmd.com/drugs/2/200231/reclast/details
[4] https://www.mayoclinic.org/diseases-conditions/osteoporosis/in-depth/osteoporosis-treatment/art-20046347
[5] https://www.drugpatentwatch.com/
[6] https://pubmed.ncbi.nlm.nih.gov/29872065/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567905/